NQMC Update Service: June 19, 2017 | NHS Scotland

NQMC Update Service: June 19, 2017

Measure Summaries

NHS Scotland

• Head and neck cancer: proportion of patients with head and neck cancer undergoing radiotherapy who receive intensity modulated radiotherapy (IMRT).
• Head and neck cancer: proportion of patients with head and neck cancer who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.
• Head and neck cancer: proportion of patients with head and neck cancer who die within 30 or 90 days of curative treatment.
• Head and neck cancer: proportion of patients with head and neck cancer who have a cytological or histological diagnosis before treatment.
• Head and neck cancer: proportion of patients with head and neck cancer who have extracapsular spread and/or final excision margins of less than 1 mm following surgical resection who receive chemoradiation.
• Head and neck cancer: proportion of patients with head and neck cancer who have oral assessment before initiation of treatment.
• Head and neck cancer: proportion of patients with head and neck cancer who smoke who are referred to smoking cessation before first treatment.
• Head and neck cancer: proportion of patients with head and neck cancer who undergo CT and/or MRI of the primary site and draining lymph nodes with CT of the chest before the initiation of treatment.
• Head and neck cancer: proportion of patients with head and neck cancer who undergo nutritional screening with the Malnutrition Universal Screening Tool (MUST) before first treatment.
• Head and neck cancer: proportion of patients with head and neck cancer with final excision margins of less than 1 mm after open surgical resection with curative intent.
• Head and neck cancer: proportion of patients with oral, pharyngeal or laryngeal cancer who are seen by a specialist speech and language therapist (SLT) before treatment.
• Renal cancer: number of renal surgical resections performed by a surgeon over a 1 year period.
• Renal cancer: proportion of patients diagnosed with renal cell carcinoma (RCC) who were clinically staged using tumour node metastases (TNM) staging system before first treatment.
• Renal cancer: proportion of patients presenting with advanced and/or metastatic renal cell carcinoma (RCC) who receive systemic anti-cancer therapy (SACT) for RCC within 12 months of diagnosis.
• Renal cancer: proportion of patients who die within 30 or 90 days of treatment for renal cell carcinoma (RCC).
• Renal cancer: proportion of patients with a diagnosis of renal cell carcinoma (RCC) receiving active treatment who undergo cross-sectional imaging of the chest, abdomen +/- pelvis before first treatment.
• Renal cancer: proportion of patients with clear cell renal cell carcinoma (RCC) who are assigned a Leibovich score following radical nephrectomy.
• Renal cancer: proportion of patients with metastatic renal cell carcinoma (RCC) who are assigned a valid prognostic score prior to commencing treatment.
• Renal cancer: proportion of patients with renal cancer who are enrolled in an interventional clinical trial or translational research.
• Renal cancer: proportion of patients with renal cell carcinoma (RCC) undergoing cryotherapy or radiofrequency ablation as their first treatment who have a histological diagnosis (confirmed by biopsy) before commencing treatment.
• Renal cancer: proportion of patients with renal cell carcinoma (RCC) undergoing systemic anti-cancer therapy (SACT) as their first treatment who have a histological diagnosis (confirmed by biopsy) before commencing treatment.
• Renal cancer: proportion of patients with renal cell carcinoma (RCC) who are discussed at the multidisciplinary team (MDT) meeting before definitive treatment.
• Renal cancer: proportion of patients with T1a renal cell carcinoma (RCC) undergoing partial nephrectomy who achieve trifecta (warm ischaemia time less than 25 minutes, negative surgical margins, and no complications).
• Renal cancer: proportion of patients with T1aN₀M₀ renal cell carcinoma (RCC) who undergo nephron sparing surgery (NSS) (laparoscopic partial nephrectomy or open partial nephrectomy).
• Sarcoma: proportion of patients with Ewing's sarcoma who are under the age of 50 who undergo neo-adjuvant combination systemic anti-cancer therapy (SACT).
• Sarcoma: proportion of patients with extremity sarcoma who are discussed at the multidisciplinary team (MDT) meeting before definitive treatment.
• Sarcoma: proportion of patients with extremity sarcoma who have a histological diagnosis before undergoing a planned surgical resection.
• Sarcoma: proportion of patients with extremity sarcoma who undergo a primary limb-sparing surgery.
• Sarcoma: proportion of patients with extremity sarcoma who undergo successful primary flap reconstruction.
• Sarcoma: proportion of patients with extremity sarcoma who undergo surgical resection with curative intent where R0 resection is achieved.
• Sarcoma: proportion of patients with extremity soft tissue sarcoma who are clinically staged using tumour node metastases (TNM) staging system prior to definitive treatment.
• Sarcoma: proportion of patients with high or moderate risk gastrointestinal stromal tumour (GIST), small bowel GISTs and primary metastatic GIST who have mutational analysis within 3 months of diagnosis.
• Sarcoma: proportion of patients with osteosarcoma who are under the age of 40 who undergo neo-adjuvant combination systemic anti-cancer therapy (SACT).
• Sarcoma: proportion of patients with sarcoma who undergo palliative oncological treatment who die within 30 days of treatment.
• Sarcoma: proportion of patients with sarcoma who undergo surgical resection or oncological treatment with curative intent who die within 30 days of treatment.
• Sarcoma: proportion of patients, aged 16 years and over, with grade 2 or 3 deep extremity soft tissue sarcoma undergoing a planned marginal or wide local excision (R0 or R1) who commenced post-operative radiotherapy within 3 months of surgery.
• Sarcoma: proportion of patients, aged 16 years and over, with high risk gastrointestinal stromal tumour (GIST) who commence adjuvant imatinib within 3 months of complete macroscopic resection.